Renin Inhibitors
1 drugsAbout Renin
Renin is a key enzyme in the renin-angiotensin-aldosterone system (RAAS) that regulates blood pressure and electrolyte balance. As a result, it is a clinically validated drug target for cardiovascular diseases. Inhibition of Renin modulates the RAAS pathway, offering a direct approach to managing hypertension.
Renin is a clinically validated target, but there is currently no genetic evidence directly linking Renin to specific diseases. Its established physiological role in blood pressure regulation underscores its importance as a therapeutic target. Further research could expand therapeutic applications within the cardiovascular area.
There is one FDA-approved drug, Aliskiren hemifumarate, targeting Renin for cardiovascular indications. This drug is a small molecule approved in 2019 by PH HEALTH. Further development of novel drug modalities could expand therapeutic options.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Alzheimer Disease with only 1 trials.
Top Drugs
PH HEALTH is the only company with an approved Renin-targeting drug.
Low competition suggests an opportunity for new entrants, but also indicates potential market challenges.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Renin, using small molecule modality.
Explore alternative modalities like antibodies or peptides to differentiate from existing therapies.
Clinical Trials 71 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 12 | 11 | 0 | 1 | 100% |
| Phase 2 | 9 | 4 | 4 | 1 | 50% |
| Phase 3 | 16 | 14 | 2 | 0 | 88% |
| Phase 4 | 34 | 23 | 11 | 0 | 68% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2019 - 2019)
The first and most recent drug approval was Aliskiren hemifumarate in 2019.
Recent entry suggests renewed interest, but a single approval indicates potential saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (10 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 11 clinical trials targeting Renin.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities